title: Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
abstract: Erdosteine (ER), a multimechanism, mucoactive agent with anti-oxidant and anti-inflammatory properties, has been shown to improve lung function, decrease plasma reactive oxygen species (ROS), and 8-isoprostane levels in patients with chronic obstructive pulmonary disease (COPD).
  
  
  
  To assess vs. placebo the effect of ER on the exercise-induced oxidative stress by measuring and comparing the release of pro-inflammatory mediators in severe COPD patients.
  
  
  
  The double blind, placebo controlled study was carried out in 24 severe (GOLD Class III) COPD patients, aged >40 yr, randomized to receive either oral ER (600 mg/day, 8 males, mean age 70.5 yr) or placebo (9 males, mean age 70.8 yr) for 10 days. All patients performed a 6-min walking test (6MWT) before and after both treatments.
  
  
  
  Mean ROS plasma levels increased significantly, but equally, in each group following the baseline 6MWT (p = ns). At the end of both treatments, a significant difference in mean plasma ROS increase from baseline became clear between the ER (+14.6% ± 2.7) and the placebo group (+24.4% ± 3.8) after the second 6MWT (p < 0.025). A similar significant trend was proved for the mean 8-isoprostane increase, which changed from baseline by +14.1% ± 2.6 in the ER, and by +26.3 ± 2.9 in the placebo group, respectively, after the second 6MWT (p < 0.006).
  
  
  
  Data from the present study are suggesting that ER is effective in reducing the release of inflammatory mediators due to the exercise-induced oxidative stress in severe COPD patients.
authors.affiliation: National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology (CESFAR), Verona, Italy. Electronic address: robertodalnegro@gmail.com.
authors.forename: Roberto W
authors.initials: RW
authors.lastname: Dal Negro
authors.affiliation: Biolab, Orlandi General Hospital, ULSS22 Regione Veneto, Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Visconti
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology; D004311:Double-Blind Method; D015444:Exercise; D005080:Exercise Test; D005100:Expectorants / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D017382:Reactive Oxygen Species / Q000097:blood; D012720:Severity of Illness Index; D013864:Thioglycolates / Q000008:administration & dosage / Q000494:pharmacology*; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D005100:Expectorants; D018836:Inflammation Mediators; D017382:Reactive Oxygen Species; D013864:Thioglycolates; D013876:Thiophenes; C048498:erdosteine
keywords: 8-Isoprostane; Chronic obstructive pulmonary disease; Erdosteine; Exercise; Oxidative stress; ROS